Unibest
← Back to patent-cliff list

SHC014748M

Tier C — Watch / trade

SHC014748M

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:PI3Kδ

Indications (approved):Chronic lymphocytic leukaemia, Peripheral T-cell lymphoma, Marginal zone B-cell lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma, Haematological malignancy

Regional status

US
-
EU
-
China
Phase II
2020-05-09
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of SHC014748M?

Approved indications include: Chronic lymphocytic leukaemia, Peripheral T-cell lymphoma, Marginal zone B-cell lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma, Haematological malignancy.

When does the SHC014748M patent expire?

No public expiry year is available for SHC014748M yet; this page updates once verified.

How do I get a quote for SHC014748M intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-07